AI in Healthcare: Where Is The Real Investment Opportunity?

Somewhere between AI-powered search engines, AI productivity tools, AI legal assistants and whatever now qualifies as an “AI-enabled workflow platform”, the term AI has become broad enough to mean almost everything and almost nothing at the same time.

That is usually what happens when a technology cycle reaches escape velocity. The excitement arrives first, the capital follows quickly behind it, and suddenly every company presentation feels one prompt away from becoming an AI business.

To be clear, some of the commercial upside being created is enormous. AI is already reshaping how businesses operate, how people search for information, how software is built, and how decisions are made. But it is becoming increasingly important to separate businesses genuinely building infrastructure from those simply attaching themselves to the narrative.

Because over time, markets tend to reward the companies solving expensive, real-world problems rather than the ones delivering the best AI-themed pitch deck.

That distinction matters even more in healthcare.

Healthcare Already Has The Problem AI Is Trying To Solve

One of the reasons healthcare feels commercially interesting right now is because the demand already exists. AI is not being introduced into a market looking for purpose. It is being introduced into systems already under enormous pressure.

Globally, healthcare providers are dealing with ageing populations, rising costs, workforce shortages, diagnostic backlogs, and increasing demand for earlier intervention. At the same time, pharmaceutical companies are investing heavily into targeted therapies and precision medicine, where timing and patient identification matter significantly more than they once did.

According to the World Health Organization, dementia has significant physical, psychological, social and economic impacts, not only for people living with dementia but also for carers, families and society. Alzheimer’s Disease International estimates that the number of people living with dementia worldwide could rise to 139 million by 2050.

The economic case is just as stark. Alzheimer’s Disease International’s dementia statistics estimate the global cost of dementia at around $1.3 trillion, a figure expected to rise as ageing populations place further pressure on healthcare systems.

For investors, those numbers create a simple but important question: what infrastructure becomes valuable if healthcare has to identify, monitor and treat disease earlier than it does today?

“Prevention Is Better Than Cure” Sounds Obvious. Scaling It Is Much Harder.

“Prevention is better than cure” is one of those phrases that sounds universally sensible until you ask what actually makes prevention possible.

Healthcare systems cannot intervene earlier if diseases are still being identified too late. Pharmaceutical companies cannot maximise targeted therapies if patients are only diagnosed once conditions have materially progressed. Precision medicine becomes difficult to deliver at scale if diagnostics remain slow, expensive, or reactive.

This is partly why diagnostics infrastructure is attracting so much attention.

The global AI in healthcare market was estimated by Grand View Research at $36.67 billion in 2025 and is projected to reach $505.59 billion by 2033. Separately, McKinsey has highlighted that AI, machine learning and deep learning could deliver net savings of up to $360 billion in healthcare spending.

The direction of travel is clear enough. Investors are no longer looking at AI in healthcare simply as a futuristic software theme. They are looking for the systems, platforms and tools that may become embedded in how healthcare is delivered.

The more practical questions become:

• Which technologies become embedded within healthcare systems?
• Which platforms become commercially difficult to replace?
• Which businesses improve outcomes while also reducing inefficiency?
• Which infrastructure becomes more valuable as adoption scales?

Few Diseases Carry The Same Emotional Weight As Alzheimer’s

One of the reasons Alzheimer’s diagnostics have become such an important area of discussion is because the disease rarely feels distant or theoretical.

Most people know somebody affected by it in some capacity. A parent, grandparent, family friend, or colleague. Often, the difficult part is not simply the diagnosis itself, but the uncertainty leading up to it. Families frequently recognise something is wrong long before medicine can clearly confirm what is happening.

That emotional reality is part of why earlier detection matters clinically, but it is also why the surrounding infrastructure is becoming commercially relevant.

As pharmaceutical companies continue developing therapies targeting earlier stages of neurodegenerative disease, the ability to identify suitable patients sooner becomes increasingly important. Companion diagnostics, biomarker analysis and AI-assisted detection are beginning to move from experimental concepts into commercially necessary infrastructure.

That does not mean every diagnostics business becomes a success story. Healthcare remains heavily regulated, scientifically complex and difficult to scale. But when technology improves lives while also addressing expensive structural problems at scale, meaningful value creation tends to follow.

The Most Interesting AI Opportunities May Sit Beneath The Surface

One of the more interesting patterns across technology cycles is that the largest long-term winners are not always the most visible consumer brands.

Sometimes the real value sits underneath the adoption curve. Cloud infrastructure quietly powered the software boom. Semiconductor businesses became essential to modern computing. Cybersecurity became increasingly valuable as digital adoption accelerated.

Healthcare may follow a similar pattern.

The conversation around AI often focuses on what consumers can immediately see: chatbots, assistants, image generation and automation tools. But in healthcare, some of the most important opportunities may sit deeper within the infrastructure layer itself.

That is where diagnostics, data interpretation, biomarker analysis and precision medicine start becoming commercially important.

One company we’ve been following closely in this space is Tivenix, a Swiss AI healthtech business focused on earlier Alzheimer’s detection through AI-driven biomarker analysis and blood-based diagnostics.

What makes the conversation around businesses like Tivenix particularly interesting is not simply the technology itself, but the broader shift it represents. As healthcare systems increasingly move towards earlier intervention and pharmaceutical companies continue investing into neurodegenerative therapies, demand for scalable diagnostic infrastructure appears likely to grow alongside it.

That intersection between commercial demand, healthcare need and AI-enabled infrastructure is where some of the more compelling private market conversations are beginning to emerge.

Looking Beyond The AI Buzzword

There is a temptation in every major technology cycle to chase visibility over substance.

Right now, parts of the AI market still feel like they are selling the sizzle rather than the steak. That does not mean the opportunity is not real. In many cases, it absolutely is. But over time, the businesses creating lasting value tend to be the ones solving meaningful problems in ways that become difficult to remove from the wider ecosystem.

Healthcare happens to offer a very large number of those problems.

If AI can genuinely help improve diagnostic accuracy, support earlier intervention, reduce inefficiency and improve patient outcomes at scale, then the commercial upside attached to that infrastructure could become significant.

Not because AI sounds exciting on a conference stage, but because systems improving lives at scale tend to become enormously valuable.

Continuing The Conversation

Join us on Thursday 28th May 2026 at 1:30PM BST for our next Investor Webinar where we will be exploring the commercial opportunity being presented by AI in healthcare.

👉 Reserve your place here